List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7051888/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Modelling neural correlates of working memory: A coordinate-based meta-analysis. NeuroImage, 2012, 60, 830-846.	4.2	777
2	Identification of genetic variants associated with Huntington's disease progression: a genome-wide association study. Lancet Neurology, The, 2017, 16, 701-711.	10.2	248
3	No double-dissociation between optic ataxia and visual agnosia: Multiple sub-streams for multiple visuo-manual integrations. Neuropsychologia, 2006, 44, 2734-2748.	1.6	244
4	Resting-state connectivity in neurodegenerative disorders: Is there potential for an imaging biomarker?. NeuroImage: Clinical, 2018, 18, 849-870.	2.7	186
5	Biological and clinical characteristics of individuals at risk for spinocerebellar ataxia types 1, 2, 3, and 6 in the longitudinal RISCA study: analysis of baseline data. Lancet Neurology, The, 2013, 12, 650-658.	10.2	167
6	Biological and clinical characteristics of the European Friedreich's Ataxia Consortium for Translational Studies (EFACTS) cohort: a cross-sectional analysis of baseline data. Lancet Neurology, The, 2015, 14, 174-182.	10.2	159
7	Clinical Spectrum of Homozygous and Heterozygous PINK1 Mutations in a Large German Family With Parkinson Disease. Archives of Neurology, 2006, 63, 833.	4.5	151
8	Multisensory integration mechanisms during aging. Frontiers in Human Neuroscience, 2013, 7, 863.	2.0	134
9	The Montreal Cognitive Assessment (MoCA) - A Sensitive Screening Instrument for Detecting Cognitive Impairment in Chronic Hemodialysis Patients. PLoS ONE, 2014, 9, e106700.	2.5	130
10	Genotype-specific patterns of atrophy progression are more sensitive than clinical decline in SCA1, SCA3 and SCA6. Brain, 2013, 136, 905-917.	7.6	128
11	Progression characteristics of the European Friedreich's Ataxia Consortium for Translational Studies (EFACTS): a 2 year cohort study. Lancet Neurology, The, 2016, 15, 1346-1354.	10.2	117
12	Morphological basis for the spectrum of clinical deficits in spinocerebellar ataxia 17 (SCA17). Brain, 2006, 129, 2341-2352.	7.6	102
13	Alternate-Form Reliability of the Montreal Cognitive Assessment Screening Test in a Clinical Setting. Dementia and Geriatric Cognitive Disorders, 2012, 33, 379-384.	1.5	93
14	Differentiated parietal connectivity of frontal regions for "what―and "where―memory. Brain Structure and Function, 2013, 218, 1551-1567.	2.3	86
15	Altered restingâ€state connectivity in Huntington's Disease. Human Brain Mapping, 2014, 35, 2582-2593.	3.6	82
16	The Metabolic Pattern of Idiopathic REM Sleep Behavior Disorder Reflects Early-Stage Parkinson Disease. Journal of Nuclear Medicine, 2018, 59, 1437-1444.	5.0	80
17	Loss of Annexin A7 Leads to Alterations in Frequency-Induced Shortening of Isolated Murine Cardiomyocytes. Molecular and Cellular Biology, 2001, 21, 4119-4128.	2.3	78
18	Brain imaging findings in idiopathic REM sleep behavior disorder (RBD) – A systematic review on potential biomarkers for neurodegeneration. Sleep Medicine Reviews, 2017, 34, 23-33.	8.5	76

#	Article	IF	CITATIONS
19	Suicidal ideation in a European Huntington's disease population. Journal of Affective Disorders, 2013, 151, 248-258.	4.1	74
20	Recessively Inherited Parkinsonism. Archives of Neurology, 2010, 67, 1357-63.	4.5	73
21	Neurofilaments in spinocerebellar ataxia type 3: blood biomarkers at the preataxic and ataxic stage in humans and mice. EMBO Molecular Medicine, 2020, 12, e11803.	6.9	73
22	Investigating function and connectivity of morphometric findings — Exemplified on cerebellar atrophy in spinocerebellar ataxia 17 (SCA17). NeuroImage, 2012, 62, 1354-1366.	4.2	72
23	Cerebral changes improved by physical activity during cognitive decline: A systematic review on MRI studies. NeuroImage: Clinical, 2019, 23, 101933.	2.7	68
24	Increased brain tissue sodium concentration in Huntington's Disease — A sodium imaging study at 4T. NeuroImage, 2012, 63, 517-524.	4.2	67
25	Neuroanatomic changes and their association with cognitive decline in mild cognitive impairment: a meta-analysis. Brain Structure and Function, 2012, 217, 115-125.	2.3	67
26	FDG PET, dopamine transporter SPECT, and olfaction: Combining biomarkers in REM sleep behavior disorder. Movement Disorders, 2017, 32, 1482-1486.	3.9	67
27	Long COVIDâ€19: Objectifying most selfâ€reported neurological symptoms. Annals of Clinical and Translational Neurology, 2022, 9, 141-154.	3.7	67
28	Morphometric fingerprint of asymptomatic <i>Parkin</i> and <i>PINK1</i> mutation carriers in the basal ganglia. Neurology, 2007, 69, 842-850.	1.1	66
29	Heterozygous carriers of a <i>Parkin</i> or <i>PINK1</i> mutation share a common functional endophenotype. Neurology, 2009, 72, 1041-1047.	1.1	66
30	Consistent Neurodegeneration and Its Association with Clinical Progression in Huntington's Disease: A Coordinate-Based Meta-Analysis. Neurodegenerative Diseases, 2013, 12, 23-35.	1.4	64
31	<i>ATP13A2</i> variants in earlyâ€onset Parkinson's disease patients and controls. Movement Disorders, 2009, 24, 2104-2111.	3.9	62
32	Cognitive decline in Parkinson's disease: the impact of the motor phenotype on cognition. Journal of Neurology, Neurosurgery and Psychiatry, 2019, 90, 171-179.	1.9	54
33	Progression characteristics of the European Friedreich's Ataxia Consortium for Translational Studies (EFACTS): a 4-year cohort study. Lancet Neurology, The, 2021, 20, 362-372.	10.2	53
34	Structural findings in the basal ganglia in genetically determined and idiopathic Parkinson's disease. Movement Disorders, 2009, 24, 99-103.	3.9	50
35	Clinical Predictors of Individual Cognitive Fluctuations in Patients Undergoing Hemodialysis. American Journal of Kidney Diseases, 2014, 64, 434-442.	1.9	50
36	Cognition in Friedreich's ataxia: a behavioral and multimodal imaging study. Annals of Clinical and Translational Neurology, 2016, 3, 572-587.	3.7	50

#	Article	IF	CITATIONS
37	Cognitive decline in Huntington's disease expansion gene carriers. Cortex, 2017, 95, 51-62.	2.4	50
38	Engineered antibodies: new possibilities for brain PET?. European Journal of Nuclear Medicine and Molecular Imaging, 2019, 46, 2848-2858.	6.4	49
39	Enhanced heterogeneity of myocardial conduction and severe cardiac electrical instability in annexin A7-deficient mice. Cardiovascular Research, 2007, 76, 257-268.	3.8	47
40	Tactile agnosia and tactile apraxia: Cross talk between the action and perception streams in the anterior intraparietal area. Behavioral and Brain Sciences, 2007, 30, 201-202.	0.7	46
41	Early Parkinson's disease: Longitudinal changes in brain activity during sequence learning. Neurobiology of Disease, 2010, 37, 455-460.	4.4	46
42	Specific and disease stage-dependent episodic memory-related brain activation patterns in Alzheimer's disease: a coordinate-based meta-analysis. Brain Structure and Function, 2015, 220, 1555-1571.	2.3	46
43	Nonataxia symptoms in Friedreich Ataxia. Neurology, 2018, 91, e917-e930.	1.1	46
44	Brain atrophy measures in preclinical and manifest spinocerebellar ataxia type 2. Annals of Clinical and Translational Neurology, 2018, 5, 128-137.	3.7	45
45	Neural correlates of impaired emotion processing in manifest Huntington's disease. Social Cognitive and Affective Neuroscience, 2014, 9, 671-680.	3.0	44
46	Neurological symptoms in COVID-19: a cross-sectional monocentric study of hospitalized patients. Neurological Research and Practice, 2021, 3, 17.	2.0	44
47	Limbic and Frontal Cortical Degeneration Is Associated with Psychiatric Symptoms in PINK1 Mutation Carriers. Biological Psychiatry, 2008, 64, 241-247.	1.3	43
48	Structural imaging in the presymptomatic stage of genetically determined parkinsonism. Neurobiology of Disease, 2010, 39, 402-408.	4.4	43
49	Evidence of the Sensitivity of the MoCA Alternate Forms in Monitoring Cognitive Change in Early Alzheimer's Disease. Dementia and Geriatric Cognitive Disorders, 2014, 37, 95-103.	1.5	43
50	Going beyond the mean: Intraindividual variability of cognitive performance in prodromal and early neurodegenerative disorders. Clinical Neuropsychologist, 2019, 33, 369-389.	2.3	43
51	Discriminating the Cortical Representation Sites of Tongue and Lip Movement by Functional MRI. Brain Topography, 2003, 16, 159-167.	1.8	42
52	Consensus Paper: Radiological Biomarkers of Cerebellar Diseases. Cerebellum, 2015, 14, 175-196.	2.5	42
53	Cognitive Improvement and Brain Changes after Real-Time Functional MRI Neurofeedback Training in Healthy Elderly and Prodromal Alzheimer's Disease. Frontiers in Neurology, 2017, 8, 384.	2.4	41
54	Conversion of individuals at risk for spinocerebellar ataxia types 1, 2, 3, and 6 to manifest ataxia (RISCA): a longitudinal cohort study. Lancet Neurology, The, 2020, 19, 738-747.	10.2	41

#	Article	IF	CITATIONS
55	Intraoperative functional MRI as a new approach to monitor deep brain stimulation in Parkinson's disease. European Radiology, 2004, 14, 686-690.	4.5	39
56	The intrinsic resting state voice network in Parkinson's disease. Human Brain Mapping, 2015, 36, 1951-1962.	3.6	38
57	Clinical manifestations of intermediate allele carriers in Huntington disease. Neurology, 2016, 87, 571-578.	1.1	37
58	Risk factors of suicidal ideation in Huntington's disease: literature review and data from Enroll-HD. Journal of Neurology, 2018, 265, 2548-2561.	3.6	37
59	Regional Brain and Spinal Cord Volume Loss in Spinocerebellar Ataxia Type 3. Movement Disorders, 2021, 36, 2273-2281.	3.9	37
60	Digitized spiral analysis is a promising early motor marker for Parkinson Disease. Parkinsonism and Related Disorders, 2010, 16, 233-234.	2.2	36
61	On the integrity of functional brain networks in schizophrenia, Parkinson's disease, and advanced age: Evidence from connectivityâ€based singleâ€subject classification. Human Brain Mapping, 2017, 38, 5845-5858.	3.6	35
62	Structural Changes Associated with Progression of Motor Deficits in Spinocerebellar Ataxia 17. Cerebellum, 2010, 9, 210-217.	2.5	33
63	Structural characteristics of the central nervous system in FriedreichÂataxia: an in vivo spinal cord and brain MRI study. Journal of Neurology, Neurosurgery and Psychiatry, 2019, 90, 615-617.	1.9	33
64	Evidence for gender differences in cognition, emotion and quality of life in Parkinson's disease?. , 2014, 5, 63-75.		33
65	Blunted Brain Energy Consumption Relates to Insula Atrophy and Impaired Glucose Tolerance in Obesity. Diabetes, 2015, 64, 2082-2091.	0.6	32
66	Impact of gender and genetics on emotion processing in Parkinson's disease - A multimodal study. NeuroImage: Clinical, 2018, 18, 305-314.	2.7	32
67	Four‥ear <scp>Followâ€up</scp> of [¹⁸ F]Fluorodeoxyglucose Positron Emission Tomography–Based Parkinson's Disease–Related Pattern Expression in 20 Patients with Isolated Rapid Eye Movement Sleep Behavior Disorder Shows Prodromal Progression. Movement Disorders, 2021, 36, 230-235	3.9	31
68	Reduced intraepidermal nerve fiber density in patients with REM sleep behavior disorder. Parkinsonism and Related Disorders, 2016, 29, 10-16.	2.2	29
69	Functional parcellation of human and macaque striatum reveals human-specific connectivity in the dorsal caudate. NeuroImage, 2021, 235, 118006.	4.2	29
70	Diminished Activation of Motor Working-Memory Networks in Parkinson's Disease. PLoS ONE, 2013, 8, e61786.	2.5	29
71	Functional connectivity modeling of consistent cortico-striatal degeneration in Huntington's disease. NeuroImage: Clinical, 2015, 7, 640-652.	2.7	27
72	Brain Structure and Degeneration Staging in Friedreich Ataxia: <scp>Magnetic Resonance Imaging</scp> Volumetrics from the <scp>ENIGMAâ€Ataxia</scp> Working Group. Annals of Neurology, 2021, 90, 570-583.	5.3	27

#	Article	IF	CITATIONS
73	Convergent patterns of structural brain changes in rapid eye movement sleep behavior disorder and Parkinson's disease on behalf of the German rapid eye movement sleep behavior disorder study group. Sleep, 2021, 44, .	1.1	26
74	Effect of MAOA Genotype on Resting-State Networks in Healthy Participants. Cerebral Cortex, 2015, 25, 1771-1781.	2.9	25
75	Functional Connectivity Differences of the Subthalamic Nucleus Related to <scp>P</scp> arkinson's Disease. Human Brain Mapping, 2016, 37, 1235-1253.	3.6	25
76	Proton Magnetic Resonance Spectroscopy of the motor cortex reveals long term GABA change following anodal Transcranial Direct Current Stimulation. Scientific Reports, 2019, 9, 2807.	3.3	25
77	Tau and neurofilament lightâ€chain as fluid biomarkers in spinocerebellar ataxia type 3. European Journal of Neurology, 2022, 29, 2439-2452.	3.3	25
78	Cognitive effects of deep brain stimulation for essential tremor: evaluation at 1 and 6Âyears. Journal of Neural Transmission, 2013, 120, 1569-1577.	2.8	23
79	Advanced brain ageing in Parkinson's disease is related to disease duration and individual impairment. Brain Communications, 2021, 3, fcab191.	3.3	23
80	Increased Cerebral Water Content in Hemodialysis Patients. PLoS ONE, 2015, 10, e0122188.	2.5	22
81	Apolipoprotein E ε4 does not affect cognitive performance in patients with Parkinson's disease. Parkinsonism and Related Disorders, 2016, 29, 112-116.	2.2	22
82	Polyglutamineâ€Expanded Ataxinâ€3: A Target Engagement Marker for Spinocerebellar Ataxia Type 3 in Peripheral Blood. Movement Disorders, 2021, 36, 2675-2681.	3.9	22
83	Naturally Occurring Autoantibodies against Tau Protein Are Reduced in Parkinson's Disease Dementia. PLoS ONE, 2016, 11, e0164953.	2.5	21
84	Blood RNA biomarkers in prodromal PARK4 and REM sleep behavior disorder show role of complexin-1 loss for risk of Parkinson's disease. DMM Disease Models and Mechanisms, 2017, 10, 619-631.	2.4	20
85	Impaired Emotional Mirroring in Parkinson's Disease—A Study on Brain Activation during Processing of Facial Expressions. Frontiers in Neurology, 2017, 8, 682.	2.4	20
86	Cognitive Decline Is Closely Associated with Ataxia Severity in Spinocerebellar Ataxia Type 2: a Validation Study of the Schmahmann Syndrome Scale. Cerebellum, 2022, 21, 391-403.	2.5	20
87	Force/shortening–frequency relationship in multicellular muscle strips and single cardiomyocytes of human failing and nonfailing hearts. Journal of Cardiac Failure, 2001, 7, 335-341.	1.7	19
88	Phenotypic spectrum of PINK1-associated parkinsonism in 15 mutation carriers from 1 family. Movement Disorders, 2007, 22, 145-147.	3.9	19
89	CAG Repeats Determine Brain Atrophy in Spinocerebellar Ataxia 17: A VBM Study. PLoS ONE, 2011, 6, e15125.	2.5	19
90	Differential Functional Connectivity Alterations of Two Subdivisions within the Right dlPFC in Parkinson's Disease. Frontiers in Human Neuroscience, 2017, 11, 288	2.0	18

#	Article	IF	CITATIONS
91	Neurochemical profiles in hereditary ataxias: A meta-analysis of Magnetic Resonance Spectroscopy studies. Neuroscience and Biobehavioral Reviews, 2020, 108, 854-865.	6.1	18
92	Functional Connectivity Changes of Key Regions for Motor Initiation in Parkinson's Disease. Cerebral Cortex, 2019, 29, 383-396.	2.9	17
93	Clinical and genetic characteristics of late-onset Huntington's disease. Parkinsonism and Related Disorders, 2019, 61, 101-105.	2.2	17
94	Friedreich and dominant ataxias: quantitative differences in cerebellar dysfunction measurements. Journal of Neurology, Neurosurgery and Psychiatry, 2018, 89, 559-565.	1.9	16
95	CSF and blood Kallikrein-8: a promising early biomarker for Alzheimer's disease. Journal of Neurology, Neurosurgery and Psychiatry, 2020, 91, 40-48.	1.9	16
96	Functional MRI for immediate monitoring stereotactic thalamotomy in a patient with essential tremor. European Radiology, 2006, 16, 2229-2233.	4.5	15
97	Tissue sodium concentration and sodium T1 mapping of the human brain at 3†T using a Variable Flip Angle method. Magnetic Resonance Imaging, 2019, 58, 116-124.	1.8	15
98	Levels of Neurofilament Light at the Preataxic and Ataxic Stages of Spinocerebellar Ataxia Type 1. Neurology, 2022, 98, .	1.1	15
99	Verbal memory declines more in female patients with Parkinson's disease: the importance of gender-corrected normative data. Psychological Medicine, 2016, 46, 2275-2286.	4.5	14
100	Quality of life in a German cohort of Parkinson's patients assessed with three different measures. Journal of Neurology, 2018, 265, 2713-2722.	3.6	14
101	Protocol of a randomized, double-blind, placebo-controlled, parallel-group, multicentre study of the efficacy and safety of nicotinamide in patients with Friedreich ataxia (NICOFA). Neurological Research and Practice, 2019, 1, 33.	2.0	14
102	Joint Multi-modal Parcellation of the Human Striatum: Functions and Clinical Relevance. Neuroscience Bulletin, 2020, 36, 1123-1136.	2.9	14
103	Reference values for the Cerebellar Cognitive Affective Syndrome Scale: age and education matter. Brain, 2021, 144, e20-e20.	7.6	14
104	Reduced Cancer Incidence in Huntington's Disease: Analysis in the Registry Study. Journal of Huntington's Disease, 2018, 7, 209-222.	1.9	14
105	PREDOMINANT DYSTONIA WITH MARKED CEREBELLAR ATROPHY: A RARE PHENOTYPE IN FAMILIAL DYSTONIA. Neurology, 2007, 68, 2157-2158.	1.1	13
106	MR imaging and spectroscopy in degenerative ataxias: toward multimodal, multisite, multistage monitoring of neurodegeneration. Current Opinion in Neurology, 2020, 33, 451-461.	3.6	13
107	Validation of a German version of the Cerebellar Cognitive Affective/ Schmahmann Syndrome Scale: preliminary version and study protocol. Neurological Research and Practice, 2020, 2, 39.	2.0	13
108	The CCAS-scale in hereditary ataxias: helpful on the group level, particularly in SCA3, but limited in individual patients. Journal of Neurology, 2022, 269, 4363-4374.	3.6	13

#	Article	IF	CITATIONS
109	The processing of lexical ambiguity in healthy ageing and Parkinson× ³ s disease: Role of cortico-subcortical networks. Brain Research, 2014, 1581, 51-63.	2.2	12
110	Brain Glucose Metabolism Heterogeneity in Idiopathic REM Sleep Behavior Disorder and in Parkinson's Disease. Journal of Parkinson's Disease, 2019, 9, 229-239.	2.8	12
111	Effect of a multicomponent exercise intervention on brain metabolism: A randomized controlled trial on Alzheimer's pathology (Dementiaâ€MOVE). Alzheimer's and Dementia: Translational Research and Clinical Interventions, 2020, 6, e12032.	3.7	12
112	Functional Characterization of Atrophy Patterns Related to Cognitive Impairment. Frontiers in Neurology, 2020, 11, 18.	2.4	12
113	Brain age and Alzheimer's-like atrophy are domain-specific predictors of cognitive impairment in Parkinson's disease. Neurobiology of Aging, 2022, 109, 31-42.	3.1	12
114	Skill Memory Escaping from Distraction by Sleep—Evidence from Dual-Task Performance. PLoS ONE, 2012, 7, e50983.	2.5	11
115	Bilingualism in Primary Progressive Aphasia. Alzheimer Disease and Associated Disorders, 2019, 33, 47-53.	1.3	11
116	Incident stroke in patients with Alzheimer's disease: systematic review and meta-analysis. Scientific Reports, 2021, 11, 16385.	3.3	11
117	Differential Temporal Dynamics of Axial and Appendicular Ataxia in <scp>SCA3</scp> . Movement Disorders, 2022, 37, 1850-1860.	3.9	11
118	Psychometric properties of the apathy evaluation scale in patients with Parkinson's disease. International Journal of Methods in Psychiatric Research, 2017, 26, .	2.1	10
119	No association between Parkinson disease and autoantibodies against NMDA-type glutamate receptors. Translational Neurodegeneration, 2019, 8, 11.	8.0	10
120	Functional MRI using multiple receiver coils: BOLD signal changes and signal-to-noise ratio for three-dimensional-PRESTO vs. single shot EPI in comparison to a standard quadrature head coil. Journal of Magnetic Resonance Imaging, 2004, 20, 321-326.	3.4	9
121	Application of Quantitative Motor Assessments in Friedreich Ataxia and Evaluation of Their Relation to Clinical Measures. Cerebellum, 2019, 18, 896-909.	2.5	9
122	Association between probable REM sleep behavior disorder and increased dermal alpha-synuclein deposition in Parkinson's disease. Parkinsonism and Related Disorders, 2022, 99, 58-61.	2.2	9
123	Changes in brain activation related to visuo-spatial memory after real-time fMRI neurofeedback training in healthy elderly and Alzheimer's disease. Behavioural Brain Research, 2020, 381, 112435.	2.2	8
124	Semiâ€automated volumetry of MRI serves as a biomarker in neuromuscular patients. Muscle and Nerve, 2020, 61, 600-607.	2.2	8
125	Cerebral Amyloid Angiopathy in Amyloid-Positive Patients from a Memory Clinic Cohort. Journal of Alzheimer's Disease, 2021, 79, 1661-1672.	2.6	8
126	Clinical predictors and neural correlates for compromised swallowing safety in Huntington disease. European Journal of Neurology, 2021, 28, 2855-2862.	3.3	8

#	Article	IF	CITATIONS
127	Characterization of Lifestyle in Spinocerebellar Ataxia Type 3 and Association with Disease Severity. Movement Disorders, 2022, 37, 405-410.	3.9	8
128	Long-Term Cognitive Decline Related to the Motor Phenotype in Parkinson's Disease. Journal of Parkinson's Disease, 2022, 12, 905-916.	2.8	7
129	Clinical diagnosis and management in early Huntington's disease: a review. Degenerative Neurological and Neuromuscular Disease, 2015, 5, 37.	1.3	6
130	Increased neural motor activation and functional reorganization in patients with idiopathic rapid eye movement sleep behavior disorder. Parkinsonism and Related Disorders, 2021, 92, 76-82.	2.2	6
131	What can 7T sodium MRI tell us about cellular energy depletion and neurotransmission in Alzheimer's disease?. Alzheimer's and Dementia, 2021, 17, 1843-1854.	0.8	6
132	The Role of Vascular Risk Factors in Biomarker-Based AT(N) Groups: A German-Dutch Memory Clinic Study. Journal of Alzheimer's Disease, 2022, 87, 185-195.	2.6	6
133	Psychometric Properties of an Abbreviated Version of the Apathy Evaluation Scale for Parkinson Disease (AES-12PD). American Journal of Geriatric Psychiatry, 2018, 26, 1079-1090.	1.2	5
134	Quantitative sensory testing and norepinephrine levels in REM sleep behaviour disorder – a clue to early peripheral autonomic and sensory dysfunction?. Journal of Neurology, 2022, 269, 923-932.	3.6	5
135	A new CERAD total score with equally weighted z-scores and additional executive and non-amnestic "CERAD-Plus" tests enhances cognitive diagnosis in patients with Parkinson's disease: Evidence from the LANDSCAPE study. Parkinsonism and Related Disorders, 2021, 90, 90-97.	2.2	5
136	Premotor Gray Matter Volume is Associated with Clinical Findings in Idiopathic and Genetically Determined Parkinson's Disease. Open Neuroimaging Journal, 2008, 2, 102-105.	0.2	5
137	Cognitive profiles of patients with mild cognitive impairment due to Alzheimer's versus Parkinson's disease defined using a base rate approach: Implications for neuropsychological assessments. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2021, 13, e12223.	2.4	4
138	The influence of disease-modifying therapy on hidden disability burden in people with newly diagnosed relapsing-remitting multiple sclerosis. Multiple Sclerosis and Related Disorders, 2022, 63, 103837.	2.0	4
139	Brain Imaging in RBD. , 2019, , 403-445.		3
140	LIPAD (LRRK2/Luebeck International Parkinson's Disease) Study Protocol: Deep Phenotyping of an International Genetic Cohort. Frontiers in Neurology, 2021, 12, 710572.	2.4	3
141	Novel CACNA1A Variant p.Cys256Phe Disrupts Disulfide Bonds and Causes Spinocerebellar Ataxia. Movement Disorders, 2021, , .	3.9	3
142	Increased brain tissue sodium concentration in Friedreich ataxia: A multimodal MR imaging study. NeuroImage: Clinical, 2022, 34, 103025.	2.7	3
143	Apraxia. , 2008, , 67-88.		2
144	Posterior Cortical Atrophy. Alzheimer Disease and Associated Disorders, 2016, 30, 276-280.	1.3	2

#	Article	IF	CITATIONS
145	D26â€Pathological tau signal in huntington's disease – an in vivo [18F]-AV-1451 pet imaging report. Journal of Neurology, Neurosurgery and Psychiatry, 2016, 87, A44.1-A44.	1.9	2
146	Disease modifying treatment trials in Parkinson's disease: how to balance expectations and interests of patients, physicians and industry partners?. Neurological Research and Practice, 2020, 2, 31.	2.0	2
147	Functional MRI Derived Resting-State Alterations in Huntington's Disease are Associated With the Distribution of Serotonergic and Dopaminergic Neurotransmitter Systems. Biological Psychiatry, 2021, 89, S172.	1.3	2
148	Sodium Image Denoising Based on a Convolutional Denoising Autoencoder. Informatik Aktuell, 2019, , 98-103.	0.6	2
149	β-Defensin Genomic Copy Number Does Not Influence the Age of Onset in Huntington's Disease. Journal of Huntington's Disease, 2013, 2, 107-124.	1.9	1
150	Quantitative sodium imaging using ultraâ€high field magnetic resonance imaging in patients with Alzheimer's disease. Alzheimer's and Dementia, 2020, 16, e042107.	0.8	1
151	Investigating Neurocognitive Functioning in Youths With Externalizing Disorders From the Philadelphia Neurodevelopmental Cohort. Journal of Adolescent Health, 2020, 69, 100-107.	2.5	1
152	Upcoming Meetings Related to Huntington's Disease. Journal of Huntington's Disease, 2013, 2, 135-135.	1.9	0
153	Ataxia. , 0, , 204-228.		0
154	D14â€Resting-state connectivity changes in huntington's disease: a follow-up study. Journal of Neurology, Neurosurgery and Psychiatry, 2016, 87, A38.3-A39.	1.9	0
155	Structural Abnormalities in Parkinson's Disease. , 2011, , 32-50.		0
156	Bildgebung genetischer Aspekte des Parkinson-Syndroms. , 2012, , 153-157.		0
157	Parkinson-Syndrom, Chorea Huntington. , 2013, , 549-561.		0
158	H32â€Neuronal correlates and clinical predictors for dysphagia in huntington's disease. , 2018, , .		0
159	Die teilautomatisierte Volumetrie der Muskel-Magnetresonanztomografie als potenzieller Biomarker bei neuromuskulÄ r en Patienten. Nervenheilkunde, 2019, 38, .	0.0	0
160	Verdachtsdiagnose: Demenz – Was ist nun zu tun?. , 0, , .		0
161	Everyday Life Tremor Signal Processing in PD Patients using BSN. , 2021, , .		0
162	Nach 1ÂJahr Deutsche Hirnstiftung: erste Meilensteine erreicht. DGNeurologie, 2022, 5, 95-96.	0.0	0

#	Article	IF	CITATIONS
163	The prevalence of vascular risk factors in different AD biomarker profiles. Alzheimer's and Dementia, 2021, 17, .	0.8	0

164 Incident stroke in patients with Alzheimer's disease: A metaâ€analysis. Alzheimer's and Dementia, 2021, 17, . 0.8 0